Modified polyrotaxane containing boric acid

By using modified polyroxane containing boric acid in boric acid in boron neutron capture therapy, the problems of insufficient blood retention and cancer cell selectivity in boron neutron capture therapy are solved, and efficient delivery of boron drugs is achieved and tumor targeting, simplifying the treatment process.

CN118900843APending Publication Date: 2024-11-05NAT UNIV CORP KUMAMOTO UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029095.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-23
Filing Date
2023-03-22
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Existing boron agents have problems with blood retention and insufficient selectivity of cancer cells in boron neutron capture therapy, resulting in the need for high doses and frequent administration and potential damage to normal tissues.

Method used

A modified polyrotaxane containing boric acid was developed by introducing multiple cyclodextrin molecules and linear molecules into the polyrotaxane and bonding the monovalent group of boric acid or its derivatives to the cyclodextrin molecule , form a new boron agent with high selectivity and blood retention.

Benefits of technology

The new boron agent significantly improves the tumor/blood concentration ratio, enhances the selectivity of cancer cells, reduces the impact on normal tissues, and can be administered in a single time, simplifying the treatment process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900843A_ABST
    Figure CN118900843A_ABST
Patent Text Reader

Abstract

The purpose of the present invention is to provide a novel compound that can be used as a component of a boron chemical. According to the present invention, provided is a modified polyrotaxane containing boric acid, the modified polyrotaxane comprising a plurality of cyclodextrin molecules, one straight-chain molecule penetrating through the openings of the plurality of cyclodextrin molecules in a stringing manner, and blocking groups disposed at both ends of the one straight-chain molecule and preventing the cyclodextrin molecules from separating from the straight-chain molecule, at least a portion of the cyclodextrin molecule is bonded to a monovalent group derived from boric acid or a derivative thereof via a linking group.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a modified polyrotaxane containing boronic acid, and more particularly to a modified polyrotaxane as a novel boronic acid-containing compound that can be used in boron neutron capture therapy. Furthermore, the present invention relates to a pharmaceutical composition comprising the modified polyrotaxane containing boronic acid. Background Art

[0002] In recent years, boron neutron capture therapy (BNCT) has attracted much attention as a new cancer treatment method. 10 B) is a non-invasive and effective radiotherapy that targets cancer cells and irradiates them with neutron beams, using radiation generated by the nuclear fission of boron to damage only cancer cells. Currently, known boron therapeutics include the first-generation boron cluster, mercaptoundecahydrododecaborate (BSH), and the second-generation boron cluster, para-borylphenylalanine (BPA), which has a single boron atom bonded to phenylalanine. Furthermore, third-generation boron therapeutics have been reported, in which boron clusters are carried on carriers such as liposomes, polymers, and polymer micelles.

[0003] BSH is a boron agent with an icosahedral molecule containing 12 boron atoms within a single molecule. While highly water-soluble, it lacks cellular uptake and selectivity for tumors. Third-generation boron agents containing BSH, using carriers such as liposomes, polymers, and polymer micelles, exploit the high permeability and retention effect (EPR effect) to selectively deliver boron to tumors. However, the EPR effect is typically achieved using carriers that exhibit long-term blood retention, making it difficult to increase the tumor-to-blood boron concentration ratio with third-generation boron agents.

[0004] BPA is the most commonly used, and it is taken up into cancer cells via amino acid transporters that are highly expressed on the surface of cancer cells. However, BPA lacks water solubility and has a low molecular weight, so it is quickly excreted from the body. In addition, even if it reaches cancer cells, it will be quickly excreted from the cancer cells via the cellular efflux mechanism. Therefore, there are problems with low blood retention and cancer aggregation. As a result, in order to maintain the boron concentration in the tumor, very high doses and continuous administration are required (about 30g is injected intravenously over 2 hours, and it is also continuously administered during neutron beam irradiation), and adverse reactions caused by high doses have also been reported. Therefore, there is a need for a boron agent that is highly selective in cancer and can be administered simply (for example, it can be administered once).

[0005] Research has been reported on a drug delivery system (DDS) that enhances the cancer accumulation of boron drugs by reversibly bonding BPA to polyvinyl alcohol to form a polymer (Patent Document 1, Non-Patent Document 1). This polymerization allows BPA to accumulate in cancer tissues via the EPR effect (passive targeting) and prevents it from being expelled from cells by transporters. This approach is highly practical because it can easily improve BPA's cancer accumulation. However, since DDS relies primarily on passive targeting, its cancer accumulation is limited (approximately 5% of the administered dose).

[0006] Furthermore, it has been reported that the retention of a boron agent in tumors can be enhanced by encapsulating the agent in PEGylated liposomes, and that the BPA concentration in tumors can be maintained at 30 μg / g tissue for at least 72 hours after intravenous administration (Non-Patent Document 2).

[0007] Generally speaking, in BNCT, in order to reduce the obstruction to normal tissues, the boron concentration in the tumor is required to be 20-40 μg. 10 B / g tissue, and a tumor / blood ratio (tumor / blood ratio: T / B ratio) or a tumor / normal tissue ratio (tumor / normal ratio: T / N ratio) of 3 or more. Therefore, a boron agent that can meet these indicators is needed.

[0008] As a method for imparting selectivity between cancer cells and tumor tissues to a carrier, it is known to utilize ligand modification with low molecules such as antibodies, peptides, sugars, vitamins, and phenylboronic acid (PBA). For example, Tang et al. reported that by modifying PBA on nanoparticles, cancer cell selective delivery can be achieved (non-patent literature 3). Deshayes et al. reported that after intravenous administration of a nanocarrier modified with PBA on a polymeric micelle, the uptake into cancer cells was significantly improved compared to a non-modified PBA group, and the therapeutic effect was enhanced (non-patent literature 4).

[0009] Cyclodextrin (CyD) is a cyclic oligosaccharide classified as a monomolecular host molecule that incorporates various drugs into its hydrophobic cavity to form inclusion complexes. It is used in a variety of fields, including food, cosmetics, clinical test drugs, membrane engineering, and polymer chemistry. In recent years, research has been actively conducted on the effective utilization of CyD supramolecules in biomaterials and drug carriers. α-CyD has been reported to form necklace-like inclusion complexes, polypseudorotaxanes (PPRXs), with polyethylene glycol (PEG). Furthermore, β-CyD, with its large cavity diameter, has been reported to selectively form PPRXs with polypropylene glycol (PPG). Furthermore, it has been reported that introducing bulky substituents into the termini of the axial polymer in PPRXs can yield polyrotaxanes (PRXs) that entrap CyD within the molecule (Non-Patent Documents 5-6). In the medical field, PPRX or PRX, in which CyD molecules are bound to receptor-recognizing sugars such as galactose and maltose, have been developed, and it has been reported that the ligands can interact multivalently with lectins while migrating (Non-Patent Documents 7-9).

[0010] Prior art literature

[0011] Patent Literature

[0012] Patent Document 1: WO2019 / 163790

[0013] Non-patent literature

[0014] Non-patent document 1: Nomoto et.al., Poly(vinyl alcohol) boosting therapeutic potential of p-boronophenylalanine in neutron capture therapy by modulating metabolism. Sci. Adv., 6, eaaz1722 (2020)

[0015] Non-patent document 2: Maruyama et al., Intracellular targeting of sodiummercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, forboron neutron-capture therapy (BNCT). J. Control. Release, 98, 195-207 (2004)

[0016] Non-patent document 3: Tang et al., Cell-Selective Messenger RNADelivery andCRISPR / Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.ACSAppl.Mater.Interfaces,11,46585-46590(2019)

[0017] Non-patent document 4: Deshayes et.al., Phenylboronic acid-installed polymericmicelles for targeting sialylated epitopes in solid tumors. J. Am. Chem. Soc., 135, 15501-15507 (2013)

[0018] Non-patent document 5: Harada et al., The molecular necklace: a rotaxane containing many threaded a-cyclodextrins. Nature, 356, 325-327 (1992)

[0019] Non-patent document 6: Jiao et al., Inclusion complexes of single-C60-end-capped poly (ethylene oxide) with cyclodextrins. Macromolecules, 35, 1399-1402 (2002)

[0020] Non-patent document 7: Nelson et al., A self-assembled multivalent pseudopolyrotaxane for

[0021] binding galectin-1.J.Am.Chem.Soc.,126,11914-11922(2004)

[0022] Non-patent document 8: Ooya et.al., Supramolecular design for multivalent interaction: maltose mobility along polyrotaxane enhanced binding withconcanavalin AJAm.Chem.Soc., 125, 13016-13017 (2003)

[0023] Non-patent document 9: Ooya et al., Effects of polyrotaxane structure on polyion complexation with DNA. Sci. Tech. Adv. Mater., 5, 363 (2004) Summary of the Invention

[0024] An object of the present invention is to provide novel compounds that can serve as components of boron pharmaceuticals.

[0025] The present inventors conducted research to provide a boron agent with improved blood retention, tumor selectivity, or at least one, preferably more, of the following: tumor-to-blood boron concentration ratio, compared to existing boron agents. During this research, the inventors realized that phenylboronic acid (PBA) itself could serve as a boron agent, thus serving as both a carrier and agent in BNTCs. They focused on PBA. PBA is a preferred ligand molecule due to its advantages: 1) it targets sialic acid (SA), a tumor marker used in clinical cancer diagnosis; 2) its small molecular weight of 184 Da makes it less likely to affect the carrier's in vivo dynamics; and 3) its low cost. The inventors conducted intensive research and discovered that modified polyrotaxanes containing boronic acid, including PBA, exhibit superior effects compared to existing boron agents, leading to the present invention.

[0026] The present invention includes the following aspects.

[0027] [1] A modified polyrotaxane containing boronic acid, comprising: a plurality of cyclodextrin molecules; a linear molecule that penetrates through the openings of the plurality of cyclodextrin molecules in a string-like manner; and end-capping groups disposed at both ends of the linear molecule to prevent the cyclodextrin molecules from separating from the linear molecule, wherein at least a portion of the cyclodextrin molecules is bonded to a monovalent group derived from boronic acid or a derivative thereof via a linking group.

[0028] [2] The boronic acid-containing modified polyrotaxane according to [1] above, wherein the monovalent group derived from boronic acid or a derivative thereof is a monovalent group derived from a phenylboronic acid derivative or a pyridineboronic acid derivative.

[0029] [3] The modified polyrotaxane containing boronic acid according to [2] above, wherein the monovalent group derived from boronic acid or a derivative thereof is a group represented by the following formula (B1) or the following formula (B2),

[0030]

[0031] (wherein, Ra represents a hydrogen atom or a halogen atom, Rb represents -(CH2)n-CO-*, -(CH2)n-NH-*, -(CH2)n-CH(NHR)CO-*, or -(CH2)n-CH(C(O)OR)NH-* (wherein * represents a bond to a linking group, n represents 0, 1, or 2, and R represents a hydrogen atom or a C1-C5 hydrocarbon group which may have a substituent)).

[0032]

[0033] (wherein, Rc represents -(CH2)n-CO-*, -(CH2)n-NH-*, -(CH2)n-CH(NHR)CO-* or -(CH2)n-CH(C(O)OR)NH-* (wherein * represents a bond to a linking group, n represents 0, 1 or 2, and R represents a hydrogen atom or a C1-C5 hydrocarbon group which may have a substituent)).

[0034] [4] The modified polyrotaxane containing boronic acid according to [3] above, wherein the monovalent group derived from boronic acid or a derivative thereof is a group represented by the following formula (B3) or the following formula (B4),

[0035]

[0036] (wherein Ra represents a hydrogen atom or a halogen atom, and Rb represents -(CH2)n-CO-*, -(CH2)n-NH-*, -(CH2)n-CH(NH2)CO-*, or -(CH2)n-CH(C(O)OH)NH-* (wherein * represents a bond to a linking group, and n represents 0 or 1)),

[0037]

[0038] (wherein Rc represents -(CH2)n-CO-*, -(CH2)n-NH-*, -(CH2)n-CH(NH2)CO-* or -(CH2)n-CH(C(O)OH)NH-* (wherein * represents a bond to a linking group and n represents 0 or 1)).

[0039] [5] The modified polyrotaxane containing boronic acid according to [4] above, wherein the monovalent group derived from boronic acid or a derivative thereof is a monovalent group derived from a boronic acid derivative selected from 4-carboxy-3-fluorophenylboronic acid, 6-carboxypyridine-3-boronic acid (5-boropyridinecarboxylic acid), 4-carboxyphenylboronic acid, p-boronic acid, 4-amino-3-fluorophenylboronic acid, and 5-aminopyridine-3-boronic acid.

[0040] [6] The boronic acid-containing modified polyrotaxane according to any one of [1] to [5] above, wherein the linear molecule is polyethylene glycol, polypropylene glycol, or a copolymer of polyethylene glycol and polypropylene glycol.

[0041] [7] The boronic acid-containing modified polyrotaxane according to any one of [1] to [6] above, wherein the end-capping group is an adamantyl group.

[0042] [8] The boronic acid-containing modified polyrotaxane according to any one of [1] to [7] above, wherein the plurality of cyclodextrin molecules are a plurality of α-cyclodextrin molecules.

[0043] [9] The modified polyrotaxane containing boronic acid according to any one of [1] to [8], wherein the linking group is represented by formula (L1):

[0044]

[0045] [Where, * 1 is the bonding site with the cyclodextrin molecule,* 2 is a bonding site with a group containing boronic acid,

[0046] R1 each independently represents a hydrogen atom, a carboxyl group which may be substituted by an alkyl group having 1 to 6 carbon atoms, a hydroxyl group which may be substituted by an alkyl group having 1 to 6 carbon atoms, a mercapto group which may be substituted by an alkyl group having 1 to 6 carbon atoms, an aryl group having 6 to 14 carbon atoms, or an alkyl group having 1 to 6 carbon atoms,

[0047] Q each independently represents -O-, -S-, -NH-, -SO2-, -CO-, -NHCO-, -CONH-, -OCO-, -COO-, -SCO-, -COS-, -NHCONH-, -NHCSNH-, -OCONH- or -NHCOO-,

[0048] a each independently represents an integer of 1 to 6,

[0049] b represents an integer from 1 to 6,

[0050] c represents an integer from 1 to 6,

[0051] X1 each independently represents -O-, -S-, -NH-, -SO2-, -CO-, -NHCO-, -CONH-, -OCO-, -COO-, -SCO-, -COS-, -NHCONH-, -NHCSNH-, -OCONH- or -NHCOO-].

[0052]

[10] The modified polyrotaxane containing boronic acid according to [9] above, wherein the linking group is represented by formula (L2),

[0053]

[0054] [Where, * 1 is the bonding site with the cyclodextrin molecule,* 2 is a bonding site with a group containing boronic acid,

[0055] d represents an integer from 1 to 6,

[0056] e represents an integer from 1 to 3,

[0057] X2 each independently represents -O-, -S-, -NH-, -SO2-, -CO-, -NHCO-, -CONH-, -OCO-, -COO-, -SCO-, -COS-, -NHCONH-, -NHCSNH-, -OCONH- or -NHCOO-].

[0058]

[11] The boronic acid-containing modified polyrotaxane according to any one of [1] to

[10] , wherein, in the polyrotaxane whose terminal group is an adamantyl group, folic acid-modified β-cyclodextrin is further bonded to the adamantyl group.

[0059]

[12] The boronic acid-containing modified polyrotaxane according to

[11] above, wherein the plurality of cyclodextrin molecules are α-cyclodextrin molecules, and the linear molecule is polyethylene glycol.

[0060]

[13] The modified polyrotaxane containing boronic acid according to any one of [1] to

[12] above, wherein the dopamine modified with polyethylene glycol is further bonded to boronic acid.

[0061]

[14] A pharmaceutical composition for boron neutron capture therapy of tumor diseases, comprising the modified polyrotaxane containing boronic acid according to any one of [1] to

[13] above, wherein the boron of the boronic acid is 10B.

[0062]

[15] A method for treating tumor diseases using boron neutron capture therapy, characterized in that a required amount of a modified polyrotaxane containing boronic acid according to any one of [1] to

[13] above is administered to a mammal, wherein the boron of the boronic acid is 10B.

[0063] According to the present invention, a novel compound containing boron can be provided. The polyrotaxane containing boric acid provided by the present invention can be used as a boron agent used in boron neutron capture therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] Figure 1 The preparation route of FPBA-PRXX (fluorophenylboronic acid-rotaxane) in Example 1 is shown.

[0065] Figure 2 The preparation route of FPBA-C (fluorophenylboronic acid-cellulose) of Comparative Example 1 is shown.

[0066] Figure 3 The results were obtained by examining the binding of Alizarin Red S (ARS) to FPBA-PRX and the inhibitory effect of sialic acid (SA). Each value represents the mean ± SEM of 6 measurements. * indicates P < 0.05 compared to FPBA-PRX. Indicates P < 0.05 compared with FPBA-PRX + SA 20 mM, ++ indicates P < 0.05 compared with FPBA-PRX + SA 30 mM, and § indicates P < 0.05 compared with FPBA-PRX + SA 40 mM.

[0067] Figure 4 A is a graph showing the results of measuring the uptake of TRITC-HP-PRX, TRITC-FPBA-PRX, and TRITC-FPBA-C into Hela cells based on polymer concentration. * indicates P < 0.05 compared to TRITC-HP-PRX. Indicates P < 0.05 compared with TRITC-FPBA-C. Figure 4 B is a graph showing the results of measuring the uptake of TRITC-FPBA-PRX and TRITC-FPBA-C into HeLa cells using FPBA concentration as a standard. * indicates P < 0.05 compared to TRITC-FPBA-C. Each value represents the mean ± SEM of 3-4 measurements.

[0068] Figure 5 A is a graph showing the results of measuring the uptake of TRITC-HP-PRX, TRITC-FPBA-PRX, and TRITC-FPBA-C into Colon-26 cells using polymer concentration as a standard. * indicates P < 0.05 compared to TRITC-HP-PRX. Indicates P < 0.05 compared with TRITC-FPBA-C. Figure 5B is a graph showing the results of measuring the uptake of TRITC-FPBA-PRX and TRITC-FPBA-C into Colon-26 cells using FPBA concentration as a standard. * indicates P < 0.05 compared to TRITC-FPBA-C. Each value represents the mean ± SEM of 3-4 measurements.

[0069] Figure 6 The results of flow cytometric analysis of TRITC-HP-PRX and TRITC-FPBA-PRX uptake into HK2 cells are shown. Each line represents representative data from 3-4 measurements.

[0070] Figure 7 The results are obtained by measuring the blood retention of TRITC-FPBA-PRX administered intravenously to mice. Each point represents the mean ± SEM of 6 measurements.

[0071] Figure 8 Results confirm the accumulation of TRITC-FPBA-PRX into tumors after intravenous administration into the tail vein of tumor-bearing mice. Each point represents the mean ± SEM of 6-9 measurements. * indicates P < 0.05 compared to TRITC-FPBA-C.

[0072] Figure 9 Results confirm the accumulation of TRITC-FPBA-PRX and TRITC-FPBA-C in various tissues after intravenous administration of tumor-bearing mice. Each point represents the mean ± SEM of six measurements. * indicates P < 0.05 compared to TRITC-FPBA-C.

[0073] Figure 10 The T / B ratios of TRITC-FPBA-PRX and TRITC-FPBA-C administered intravenously to tumor-bearing mice were measured. Each point represents the mean ± SEM of 6-9 measurements. * indicates P < 0.05 compared to TRITC-FPBA-C.

[0074] Figure 11 This is a diagram schematically showing how folic acid-modified β-CyD or PEG-dopamine is bound to the boronic acid-containing modified polyrotaxane of the present invention.

[0075] Figure 12 The results are obtained by evaluating the intracellular uptake of TRITC-FPBA-PRX / FA7-β-CyD. Each value represents the mean ± SEM of three measurements.

[0076] Figure 13The results of evaluating the intracellular uptake of TRITC-FPBA-PRX / PEG-dopamine are shown. Each value represents the mean ± SEM of 6 measurements. * indicates P < 0.05 compared with FPBA-PRX. = indicates P < 0.05 compared with FPBA-PRX + PEG dopamine 220 μM, ++ indicates P < 0.05 compared with FPBA-PRX + PEG dopamine 440 μM TRITC-FPBA-C.

[0077] Figure 14 Results from examining the effect of pH on TRITC-FPBA-PRX / PEG-dopamine. The left column represents pH 7.4, and the right column represents pH 6.5 for each condition. Each value represents the mean ± SEM of 5-6 measurements. * indicates P < 0.05 compared to the control.

[0078] Figure 15 Results confirming the cytotoxicity of FPBA-PRX against cancer cells. The left column shows the results for trypsin alone at each time point, while the right column shows the results for trypsin plus FPBA-PRX. Each value represents the mean ± SEM of four measurements. * indicates P < 0.05 compared to the control (trypsin).

[0079] Figure 16 The results confirm the antitumor effect of FPBA-PRX. The average value of tumor size in the non-neutron irradiated group is set as 100%, and the average value of tumor size in the irradiated group is shown. DETAILED DESCRIPTION

[0080] Below, take the embodiment of illustration as example, the present invention is described together with the preferred method and material that can be used in the enforcement of the present invention, but the present invention is not limited to the mode of following record.It should be noted that as long as there is no special instructions in the text, all technical terms and scientific terms used in this specification have the same meaning as the meaning usually understood by those skilled in the art of the technical field to which the present invention belongs.In addition, any material and method that is equal or identical to the material and method of recording in this specification can be used similarly in the enforcement of the present invention.In addition, all publications and patents cited in this specification as relevant to the present invention are cited in this specification and constitute a part for this specification as the content of the method, material or other situations that can be used in the present invention.

[0081] In this specification, the term "A to B" when describing a numerical range means that the numerical range includes the endpoints A and B. "A to B" has the same meaning. In this specification, "about" is used to mean that ±10% is allowed.

[0082] [Polyrotaxane]

[0083] The boronic acid-containing modified polyrotaxane of the present invention is composed of multiple cyclodextrin molecules, a linear molecule, and bulky end-capping groups disposed at both ends of the linear molecule. The linear molecule has a structure that penetrates the openings of the multiple cyclodextrin molecules in a thread-like manner, and the bulky end-capping groups prevent the cyclodextrin molecules from separating from the linear molecule. The boronic acid-containing modified polyrotaxane of the present invention is characterized in that at least a portion of the cyclodextrin molecules is bonded to the boron-containing group via a linking group. Figure 1 Schematic diagram showing a modified polyrotaxane containing boronic acid. In the modified polyrotaxane containing boronic acid of the present invention, since it can exist as a boronic acid group such as RB(OH)2, it can be bonded to sialic acid (SA) that is highly expressed on the surface of cancer cells, for example.

[0084] [Cyclodextrin]

[0085] Examples of cyclodextrin molecules include α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin. Any cyclodextrin can be used in the present invention, but α-cyclodextrin or β-cyclodextrin is preferred, with α-cyclodextrin being more preferred. Some or all of the hydroxyl groups of the cyclodextrin molecules are bonded to the boronic acid-containing group via a linking group.

[0086] [Boric acid or its derivatives]

[0087] In the present invention, boronic acid or its derivative refers to a compound in which the hydroxyl group of the boronic acid is substituted by an optionally substituted alkyl group having 1 to 6 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl), an optionally substituted cycloalkyl group having 3 to 6 carbon atoms, an optionally substituted alkenyl group having 1 to 6 carbon atoms, an optionally substituted alkynyl group having 1 to 6 carbon atoms, an optionally substituted aryl group having 5 to 14 carbon atoms (e.g., phenyl, naphthyl, anthracenyl, fluorenyl), an optionally substituted 5-14-membered heteroaryl group (e.g., furyl, benzofuranyl, pyridyl, pyrimidinyl, quinolyl), an optionally substituted arylene group having 5 to 14 carbon atoms, or an optionally substituted 5-14-membered heteroarylene group, preferably a compound substituted by an optionally substituted phenyl group or an optionally substituted pyridyl group.

[0088] Examples of the substituents in the phrase "may be substituted" include halogen atoms (e.g., fluorine, chlorine, and bromine), amino groups, carboxyl groups, nitro groups, cyano groups, oxy groups, hydroxyl groups, formyl groups, carbamoyl groups, thiocarbamoyl groups, formylamino groups, alkyl groups having 1 to 20 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, 2-ethylhexyl, octyl, dodecyl, and dodecyloctyl), aryl groups (e.g., phenyl, naphthyl, and fluorenyl), aralkyl groups (e.g., benzyl and phenethyl), and alkoxy groups (e.g., methoxy and ethoxy). The number of substituents in the phrase "may be substituted" is, for example, 1 to 3, preferably 1 to 2. When there are two or more substituents, the substituents may be the same or different. The carbon atoms in these substituents are not counted toward the number of carbon atoms in the alkyl group and the like.

[0089] In addition, examples of the boronic acid or its derivatives in the present invention include compounds described in WO2019 / 004482, JP-A-2019-506915, JP-A-2019-503372, and JP-A-2019-513493.

[0090] As the boronic acid or its derivative in the present invention, preferably, phenylboronic acid derivatives or pyridineboronic acid derivatives can be mentioned, but it is not limited thereto. Specifically, 4-carboxy-3-fluorophenylboronic acid, 6-carboxypyridine-3-boronic acid (5-boropyridinecarboxylic acid), 4-carboxyphenylboronic acid, p-boronic phenylalanine, 4-amino-3-fluorophenylboronic acid and 5-aminopyridine-3-boronic acid can be mentioned. The synthesis of the boronic acid derivative can be carried out according to a known method.

[0091] The monovalent group derived from boronic acid or its derivative contained in the boronic acid-containing modified polyrotaxane of the present invention refers to the monovalent group derived from the above-mentioned boronic acid or its derivative, and examples thereof include a group represented by the following formula (B1) and a group represented by the following formula (B2).

[0092]

[0093] (wherein, Ra represents a hydrogen atom or a halogen atom, Rb represents -(CH2)n-CO-*, -(CH2)n-NH-*, -(CH2)n-CH(NHR)CO-*, or -(CH2)n-CH(C(O)OR)NH-* (wherein * represents a bond to a linking group, n represents 0, 1, or 2, and R represents a hydrogen atom or a C1-C5 hydrocarbon group which may have a substituent)

[0094]

[0095] (wherein, Rc represents -(CH2)n-CO-*, -(CH2)n-NH-*, -(CH2)n-CH(NHR)CO-* or -(CH2)n-CH(C(O)OR)NH-* (wherein * represents a bond to a linking group, n represents 0, 1 or 2, and R represents a hydrogen atom or a C1-C5 hydrocarbon group which may have a substituent).

[0096] Preferred examples include groups represented by the following formula (B3) and groups represented by the following formula (B4).

[0097]

[0098] (wherein Ra represents a hydrogen atom or a halogen atom, and Rb represents -(CH2)n-CO-*, -(CH2)n-NH-*, -(CH2)n-CH(NH2)CO-*, or -(CH2)n-CH(C(O)OH)NH-* (wherein * represents a bond to a linking group, and n represents 0 or 1)

[0099]

[0100] (wherein Rc represents -(CH2)n-CO-*, -(CH2)n-NH-*, -(CH2)n-CH(NH2)CO-* or -(CH2)n-CH(C(O)OH)NH-* (wherein * represents a bond to a linking group and n represents 0 or 1).

[0101] Examples of the halogen atom in the above formula include fluorine, chlorine, bromine and iodine, with fluorine being preferred.

[0102] Examples of the C1-C5 hydrocarbon group in the above formula include a methyl group, an ethyl group, a propyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, and a neopentyl group.

[0103] Examples of the substituents in the "optionally substituted" group in the above formula include halogen atoms (e.g., fluorine, chlorine, and bromine), amino groups, carboxyl groups, nitro groups, cyano groups, oxo groups, hydroxyl groups, formyl groups, carbamoyl groups, thiocarbamoyl groups, formylamino groups, alkyl groups having 1 to 20 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, 2-ethylhexyl, octyl, dodecyl, and dodecyloctyl), aryl groups (e.g., phenyl, naphthyl, and fluorenyl), aralkyl groups (e.g., benzyl and phenethyl), and alkoxy groups (e.g., methoxy and ethoxy). The number of substituents in the "optionally substituted" group is, for example, 1 to 3, preferably 1 to 2. When there are two or more substituents, the substituents may be the same or different. The carbon atoms in these substituents are not counted toward the number of carbon atoms in the alkyl group and the like.

[0104] More preferably, a monovalent group derived from 4-carboxy-3-fluorophenylboronic acid, 6-carboxypyridine-3-boronic acid (5-boropyridinecarboxylic acid), 4-carboxyphenylboronic acid, p-boronophenylalanine, 4-amino-3-fluorophenylboronic acid, or 5-aminopyridine-3-boronic acid is mentioned.

[0105] In one embodiment of the present invention, a monovalent group derived from boronic acid or a derivative thereof that exhibits binding ability to sialic acid (SA) highly expressed on the surface of cancer cells is preferred. 4-Carboxy-3-fluorophenylboronic acid and 6-carboxypyridine-3-boronic acid are particularly preferred because they exhibit strong binding ability to SA.

[0106] [Linking group]

[0107] The above-mentioned monovalent group from boric acid or its derivative is bonded to part or all of the cyclodextrin molecule via a linking group. The introduction of the linking group into the cyclodextrin is not limited thereto and, for example, can be carried out by the following method. Utilize propylene oxide to hydroxypropylate part or all of the hydroxyl groups of the cyclodextrin, and thereafter, add the compound that becomes the linking group. As needed, in order to promote the reaction, a catalyst can be added. Thus, a polyrotaxane can be obtained in which the compound that becomes the linking group, which has a reactive group at one end, is introduced into the cyclodextrin via the hydroxyl group and / or the hydroxyl group of the hydroxypropyl group. The introduction of the compound that becomes the linking group into the cyclodextrin can utilize propylene oxide etc. to hydroxyalkylate the hydroxyl groups of the cyclodextrin, or it can not be hydroxyalkylated, but it is preferably hydroxyalkylated. In one embodiment of the present invention, the hydroxypropyl group introduced into the cyclodextrin is a 2-hydroxypropyl group. In addition, the end of the hydroxypropyl group that introduces the hydroxyl group of the cyclodextrin can also be further modified according to the linking group to be introduced.

[0108] The compound that can be used as a linking group in the present invention is not particularly limited as long as it can bind the above-mentioned monovalent group from boric acid or its derivatives to cyclodextrin. Preferably, it is a compound having a reactive group with the hydroxyl group of cyclodextrin and / or the hydroxyl group of hydroxypropyl at one end and a reactive group with the functional group of the above-mentioned boric acid or its derivatives at the other end. In addition, when the end of the hydroxypropyl group is further modified, it is preferred to use a compound having a reactive group with the modified end at one end and a reactive group with the functional group of the above-mentioned boric acid or its derivatives at the other end as a linking group. Although not limited to this, the compound that can be used as a linking group can be exemplified by a compound represented by the following formula (La).

[0109]

[0110] [wherein, R1 each independently represents a hydrogen atom, a carboxyl group which may be substituted by an alkyl group having 1 to 6 carbon atoms, a hydroxyl group which may be substituted by an alkyl group having 1 to 6 carbon atoms, a mercapto group which may be substituted by an alkyl group having 1 to 6 carbon atoms, an aryl group having 6 to 14 carbon atoms, or an alkyl group having 1 to 6 carbon atoms,

[0111] Q each independently represents -O-, -S-, -NH-, -SO2-, -CO-, -NHCO-, -CONH-, -OCO-, -COO-, -SCO-, -COS-, -NHCONH-, -NHCSNH-, -OCONH- or -NHCOO-,

[0112] a each independently represents an integer of 1 to 6,

[0113] b represents an integer from 1 to 6,

[0114] c represents an integer from 1 to 6,

[0115] X a each independently represents -OH, -SH, -NH2, -SO3H, -COOH, -NHCOOH, -CONH2, -OCOOH, -COOH, -SCOOH, -COSH, -NHCONH2, -NHCSNH2, -OCONH2 or -NHCOOH].

[0116] Examples of the alkyl group having 1 to 6 carbon atoms include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0117] Examples of the aryl group having 6 to 14 carbon atoms include phenyl, 1-naphthyl, 2-naphthyl, 1-anthryl, 2-anthryl, and 9-anthryl.

[0118] Preferred examples include compounds represented by the following formula (Lb).

[0119]

[0120] [wherein, d represents an integer of 1 to 6, e represents an integer of 1 to 3, and X b each independently represents -OH, -SH, -NH2, -SO3H, -COOH, -NHCOOH, -CONH2, -OCOOH, -COOH, -SCOOH, -COSH, -NHCONH2, -NHCSNH2, -OCONH2 or -NHCOOH].

[0121] The method for introducing the compound serving as the linking group into the cyclodextrin can be appropriately selected, for example, based on the reactive group possessed by the compound serving as the linking group that reacts with the hydroxyl group of the cyclodextrin and / or the terminal group of the introduced hydroxypropyl group. Furthermore, the bond between the monovalent group derived from boronic acid or its derivative and the compound serving as the linking group introduced into the cyclodextrin can be appropriately selected based on the reactive group possessed by the compound serving as the linking group that reacts with the reactive groups of these groups.

[0122] Although not limited thereto, for example, when the compound serving as the linking group has an amino group as a reactive group with the hydroxyl group of the hydroxypropyl group introduced into the cyclodextrin, the compound serving as the linking group can be introduced into the cyclodextrin via an amide bond by using, for example, CDI as a catalyst. Furthermore, when the reactive group at the other end of the compound serving as the linking group introduced into the cyclodextrin is an amino group, and when the boronic acid or its derivative has a carboxyl group, for example, by using NHS and EDC as catalysts to activate the carboxyl group and cause a reaction, the boronic acid or its derivative can be bonded to the cyclodextrin via an amide bond through the linking group.

[0123] The content ratio of boronic acid in the modified polyrotaxane containing boronic acid can be arbitrarily adjusted by changing the addition ratio of boronic acid or its derivatives relative to cyclodextrin. The content ratio of boronic acid or its derivatives (boric acid content ratio) can be expressed as either a ratio relative to one molecule of polyrotaxane or a ratio relative to the bonded cyclodextrin. The content ratio of boronic acid is preferably 0.1 to 5.0, more preferably 0.2 to 3.0, and further preferably 0.5 to 2.0, relative to one molecule of cyclodextrin. Alternatively, the content ratio of boronic acid is preferably 5 to 400, more preferably 10 to 200, and further preferably 20 to 100, relative to one molecule of polyrotaxane.

[0124] [Linear molecule]

[0125] The linear molecules of the modified polyrotaxane of the present invention are not particularly limited as long as they are compounds that penetrate the opening of the cyclodextrin and have functional groups that can react with the end-capping groups. As linear molecules preferably used, polyalkylene glycols such as polyethylene glycol, polypropylene glycol, and polytetramethylene glycol, terminal hydroxyl polyolefins such as polybutadiene glycol, polyisoprene glycol, polyisobutylene glycol, poly(acrylonitrile-butadiene) glycol, hydrogenated polybutadiene glycol, polyethylene glycol, and polypropylene glycol, polyesters such as polycaprolactone diol, polylactic acid, polyethylene adipate, polybutylene adipate, polyethylene terephthalate, and polybutylene terephthalate, or copolymers of these molecules are preferred. From the perspective of easy synthesis of polyrotaxanes, polyethylene glycol, polypropylene glycol, and copolymers of polyethylene glycol and polypropylene glycol (e.g., PEG-PPG-PEG, etc.) are preferred.

[0126] Examples of the linear molecule further include terminal functional polysiloxanes such as terminal silanol-type polydimethylsiloxane having a functional group at the terminal, terminal amino chain polymers such as terminal amino polyethylene glycol, terminal amino polypropylene glycol, and terminal amino polybutadiene, terminal carboxyl chain polymers such as terminal carboxyl polyethylene glycol, terminal carboxyl polypropylene glycol, and terminal carboxyl polybutadiene, and trifunctional or higher polyfunctional chain polymers having three or more of the above functional groups in one molecule. Among them, terminal amino polyethylene glycol, terminal carboxyl polyethylene glycol, terminal amino polypropylene glycol, terminal carboxyl polypropylene glycol, terminal amino polypropylene glycol-polypropylene glycol copolymers, and terminal carboxyl polypropylene glycol-polypropylene glycol copolymers are preferred.

[0127] The weight-average molecular weight of the linear molecule is 2 kDa or greater, preferably 3 kDa or greater, more preferably 5 kDa or greater, and 200 kDa or less, preferably 100 kDa or less, and more preferably 50 kDa or less. The linear molecule having a molecular weight within this range allows the modified polyrotaxane containing boronic acid to contain a sufficient amount of cyclodextrin and boronic acid and exhibit favorable solubility. The weight-average molecular weight is a polystyrene-equivalent value measured by gel filtration chromatography (GPC).

[0128] In the boronic acid-containing modified polyrotaxane of the present invention, the number of cyclodextrin molecules included in the linear molecule (inclusion amount), when the maximum inclusion amount is set to 1, is preferably 0.01 to 0.6, more preferably 0.05 to 0.5, further preferably 0.1 to 0.4, and particularly preferably 0.2 to 0.3. By keeping the number of cyclodextrins within this range, there is a tendency to achieve a balance between the mobility and solubility of the cyclodextrin. It should be noted that the maximum inclusion amount of cyclodextrin is a theoretical value determined by the molecular chain length of the linear molecule and the cavity height of the cyclodextrin.

[0129] The maximum inclusion capacity of cyclodextrin molecules can be determined based on the length of the linear molecule and the thickness of the cyclodextrin molecule in the chain direction. For example, when the linear molecule is polyethylene glycol and the cyclodextrin molecule is α-cyclodextrin, the maximum inclusion capacity can be determined experimentally as described in Macromolecules 1993, 26, 5698-5703. For example, when 20 kDa polyethylene glycol is used as the linear molecule, the maximum inclusion capacity is 227 α-cyclodextrin molecules.

[0130] [Capping Group]

[0131] The end-capping groups of the modified polyrotaxane of the present invention may be any groups as long as they are located at both ends of the linear molecule and do not cause cyclodextrin to separate from the linear molecule. Preferred examples include bulky groups and ionic groups, with bulky groups being preferred. Such end-capping groups may be used singly or in combination.

[0132] Examples of the above-mentioned end-capping groups include dinitrophenyl groups such as 2,4-dinitrophenyl and 3,5-dinitrophenyl, groups derived from cyclodextrin, adamantyl groups, adamantylamino groups, trityl groups, fluoresenyl groups, pyrene groups, substituted phenyl groups (as substituents, alkyl groups, alkoxy groups, hydroxyl groups, halogen groups, cyano groups, sulfonyl groups, carboxyl groups, amino groups and phenyl groups can be mentioned, but are not limited to these. The substituents may be one or more), substituted polycyclic aromatic groups (as substituents, the same groups as mentioned above can be mentioned, but are not limited to these. The substituents may be one or more), and steroids.

[0133] Among these, from the viewpoint of ease of introduction of a blocking group, dinitrophenyl, a group derived from cyclodextrin, adamantyl, adamantylamino, trityl, fluoresenyl, and pyrenyl are preferred, and adamantyl, adamantylamino, and trityl are more preferred.

[0134] By reacting a compound having a portion that becomes an end-capping group and a group that reacts with functional groups present at both ends of the linear molecule with the linear molecule, the end-capping group can be introduced into both ends of the linear molecule. The introduction can be carried out by referring to a known method, for example, the method described in WO2005-080469 can be used.

[0135] The weight average molecular weight of the boronic acid-containing polyrotaxane of the present invention is preferably in the range of 10 to 1000 kDa, more preferably in the range of 20 to 500 kDa, and even more preferably in the range of 50 to 200 kDa. A weight average molecular weight within this range tends to improve blood retention and tumor aggregation.

[0136] The boronic acid-containing polyrotaxane of the present invention can be produced, for example, by the following steps: mixing cyclodextrin with a linear molecule, allowing the linear molecule to penetrate the opening of the cyclodextrin in a thread-like manner, thereby including the linear molecule in the cyclodextrin to obtain a pseudopolyrotaxane; capping both ends of the linear molecule of the obtained pseudopolyrotaxane with a capping group to prevent the cyclodextrin from being separated from the threaded state; hydroxypropylating some or all of the hydroxyl groups of the cyclodextrin in the obtained polyrotaxane with propylene oxide; reacting the hydroxyl groups of the cyclodextrin and / or the hydroxyl groups of the hydroxypropyl groups with a compound serving as a linking group to obtain a polyrotaxane into which the compound serving as a linking group is introduced; and reacting boronic acid or a derivative thereof with the compound serving as a linking group to obtain a boronic acid-containing modified polyrotaxane in which a monovalent group derived from the boronic acid or its derivative is bonded to the cyclodextrin via the linking group.

[0137] The boronic acid-containing polyrotaxanes of the present invention can also be converted into borate esters by bonding sugars to the boronic acid moiety, thereby improving solubility. The sugar can be appropriately selected from known sugars, for example, sugar alcohols such as sorbitol, mannitol, xylitol, and erythritol; monosaccharides such as glucose, fructose, mannose, and galactose; disaccharides such as sucrose, trehalose, lactose, and maltose; or oligosaccharides, preferably glucose, fructose, and sucrose. The sugars may be one or more.

[0138] [Pharmaceutical composition]

[0139] The modified polyrotaxane containing boronic acid of the present invention has an anticancer effect, so it can be used as an anticancer agent by itself. In addition, since it contains a boron atom, it can also be used as a boron agent using 10B or as an agent for BNCT. Therefore, the pharmaceutical composition containing the modified polyrotaxane containing boronic acid of the present invention as an active ingredient can also utilize the aggregation of the modified polyrotaxane containing boronic acid to tumor cells and the selective uptake into cancer cells via sialic acid, as well as the use of high-LET radiation alpha particles ( 4 He particles) and 7 A pharmaceutical composition that can be used in boron neutron capture therapy (BNTC) in which Li particles destroy only cancer cells.

[0140] The modified polyrotaxane containing boronic acid of the present invention can be used directly as a drug for BNCT, or can be formulated into various dosage forms using pharmaceutically acceptable carriers or excipients by methods known to those skilled in the art. The carriers or excipients used are well known to those skilled in the art and can be appropriately selected. For example, cross-linking agents, dissolving agents, emulsifiers, moisturizers, cooling agents, inorganic powders, antioxidants, preservatives, colorants, flavoring agents, pH regulators, stabilizers can be mentioned, but are not limited to these. The pharmaceutical composition of the present invention can be manufactured using means and methods known to those skilled in the art. For example, when manufacturing injections or infusions, pharmaceutically acceptable carriers such as physiological saline and phosphate-buffered saline can be used. When preparing the pharmaceutical composition of the present invention, pharmaceutically acceptable additives such as thickeners, absorption promoters, pH regulators, preservatives, dispersants, wetting agents, stabilizers, preservatives, suspending agents, and surfactants can be used. Since the boronic acid-containing modified polyrotaxane in the pharmaceutical composition of the present invention is also a carrier molecule, it can be used directly by conventional drug administration in radiotherapy or the like without using other carrier molecules.

[0141] The dosage form of the pharmaceutical composition of the present invention is not particularly limited and can be appropriately selected according to the position, size, type, patient's condition, etc. of the cancer to be treated. The medicament of the present invention can be any of liquid, semisolid, and solid. Examples of the dosage form of the medicament of the present invention include injections, infusions, nasal drops, eye drops, sprays, lotions, creams, gels, ointments, powder coatings, liquid coatings, patches, other transdermal absorbents, suppositories, tablets, capsules, powders, granules, syrups, aerosols, inhalants, transmucosal agents, etc., but are not limited to these. Alternatively, the medicament of the present invention can also be in the form of a freeze-dried product suspended in a pharmaceutically acceptable carrier such as physiological saline or phosphate-buffered saline when administered. The pharmaceutical composition of the present invention is preferably in the form of a liquid.

[0142] The administration route of the pharmaceutical composition of the present invention is also not particularly limited and can be appropriately selected according to the site, size, type, and condition of the cancer to be treated. Examples of the administration route of the pharmaceutical composition of the present invention include systemic administration and local administration, but are not limited thereto. Examples include subcutaneous, intradermal, intramuscular, intravenous, intradrip, intraarterial (e.g., via the carotid artery), intramedullary, intraarachnoid, intraventricular, intraperitoneal, or intranasal administration, oral administration, transmucosal administration, enteral administration, eye drops, ear drops, inhalation, transdermal administration, and intratumoral administration. Preferably, the administration is intravenous or subcutaneous.

[0143] The pharmaceutical composition of the present invention can be administered to mammals (e.g., humans, cattle, horses, pigs, dogs, cats, monkeys, mice, rats, and especially humans). The preferred administration form, formulation form, etc. can be appropriately selected by the physician based on the age, sex, constitution, symptoms, treatment period, etc. of the subject (patient). In addition, the dosage of the pharmaceutical composition of the present invention can be appropriately determined by the physician based on the type, site, size, type, and state of the subject (patient) of the cancer to be treated. The dosage of the modified polyrotaxane containing boronic acid of the present invention to humans can be appropriately determined based on the above-mentioned conditions of the subject. When the pharmaceutical composition of the present invention is used for BNCT, it is preferably an administration amount that can achieve the concentration of boron 10 in the tumor tissue shown below.

[0144] When the pharmaceutical composition of the present invention is used for BNCT, any method of administration may be used as long as it can deliver the modified polyrotaxane containing boronic acid to the vicinity of the tumor, but intravenous administration, intraperitoneal administration, or transdermal administration is preferred. Furthermore, when the pharmaceutical composition of the present invention is used for diagnostics used in PET, intravenous administration is preferred.

[0145] When the polyrotaxane containing boronic acid of the present invention is used for BNCT, it can be used as follows, for example, but is not limited thereto. When the polyrotaxane containing boronic acid of the present invention is used for BNCT, it is preferably used as an intravenous drip. Before irradiation, the injection solution containing the polyrotaxane containing boronic acid of the present invention can be administered to the subject (patient or animal) in advance, and after adjusting the boron 10 to accumulate in the tumor, the epithermal neutron beam is irradiated. Alternatively, the injection solution of the present invention can be administered to the subject in advance before irradiation, and after adjusting the boron 10 to accumulate in the tumor, the epithermal neutron beam is irradiated while further administration is continued. The dosage of the injection solution of the present invention is not particularly limited, but can be controlled to achieve a preferred intracellular boron concentration. Such an administration amount can be set according to the type of tumor to be applied, the degree of progression, the age and weight of the subject, etc. When the injection solution of the present invention is used for intravenous administration, it is administered intravenously at a rate of about 200 to about 500 ml per hour for 1.5 to 4.0 hours, preferably 2.0 to 3.6 hours. The timing of starting administration may be before the start of neutron irradiation, or it may be performed continuously from before the start of irradiation to the irradiation period.

[0146] The amount of boric acid-containing polyrotaxane administered in BNCT is not particularly limited as long as it can effectively inhibit (kill) tumor cells by neutron beam irradiation. For example, the concentration of boron 10 in tumor tissue is preferably about 10 ppm (about 50 boron 10 atoms per cell) to about 100 ppm, more preferably about 20 ppm to about 60 ppm, and more preferably about 30 ppm to about 40 ppm.

[0147] Neutron beam irradiation is preferably controlled to efficiently generate epithermal neutrons in tumor cells, with the resulting α-rays and 7Li particles killing only tumor cells. The dose can be calculated based on the boron concentration in the blood and the neutron fluence delivered to the tissue. This dose can be multiplied by the relative bioavailability (RBE) of the polyrotaxane containing boric acid to calculate the X-ray equivalent dose.

[0148] Positron emission tomography can also be used to measure aggregation before administering the boronic acid-containing polyrotaxane of the present invention. For example, in addition to the boronic acid-containing polyrotaxane, a radioactive compound obtained by labeling the boronic acid-containing polyrotaxane with the radionuclide 18F (18F-boronic acid-containing polyrotaxane) can be administered, and its whole-body distribution can be imaged using PET examination to estimate the aggregation property of the boron compound. Although not limited to this, administration is preferably performed to subjects whose boron concentration ratio in cancer tissue / normal tissue is 3 or greater in such PET examination.

[0149] Cancers for which the 10B agent using the boronic acid-containing modified polyrotaxane of the present invention can be applied are not particularly limited, and examples include lymphoma (Hodgkin's and non-Hodgkin's), carcinoma, solid tissue cancer, squamous cell carcinoma, adenocarcinoma, sarcoma, glioma, high-grade glioma, blastoma, neuroblastoma, plasmacytoma, histiocytoma, melanoma, hypoxic tumors, myeloma, AIDS-related lymphoma or sarcoma, metastatic cancer, and all cancers.

[0150] More specifically, the cancer may include lymphoma, B-cell lymphoma, T-cell lymphoma, mycosis fungoides, Hodgkin's disease, myeloid leukemia, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, squamous cell carcinoma of the head and neck, kidney cancer, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), neuroblastoma / glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, squamous cell carcinoma of the mouth, pharynx, larynx and lung, colon cancer, cervical cancer, uterine cervix cancer, breast cancer, epithelial cancer, kidney cancer, genitourinary cancer, lung cancer, esophageal cancer, stomach cancer, head and neck cancer, colorectal cancer, hematopoietic cancer; testicular cancer; colon cancer and rectal cancer, or pancreatic cancer.

[0151] When the pharmaceutical composition of the present invention is used in BNCT, the pharmaceutical composition of the present invention is administered to a patient, and after the boronic acid-containing polyrotaxane of the present invention has sufficiently reached the treatment site, neutron irradiation is performed. Neutron irradiation can be performed using a nuclear reactor or accelerator-type neutron generator to determine various conditions required for treatment, such as the neutron dose, neutron energy spectrum, and irradiation time.

[0152] Administration of the pharmaceutical composition of the present invention and neutron irradiation can be performed once or multiple times. However, because the boric acid-containing polyrotaxane of the present invention exhibits excellent selectivity and aggregating properties toward cancer cells, sufficient effects can be expected with fewer administrations and neutron irradiations. Furthermore, the interval between administration and neutron irradiation can be shortened compared to conventional boron-based agents. The actual number of administrations and neutron irradiation sessions can be determined by the physician based on the location and type of cancer, the degree of cancer reduction, and the patient's condition.

[0153] The pharmaceutical composition of the present invention can be used in combination with known chemotherapy, surgical therapy, radiotherapy, thermotherapy, immunotherapy, and the like.

[0154] Although not being bound by this theory, in the modified polyrotaxane containing boronic acid of the present invention, the cyclodextrins strung together by linear molecules are able to move freely on the linear molecules. Therefore, when they reach the vicinity of target cells, the boronic acid molecules (e.g., phenylboronic acid derivatives) bound to the cyclodextrins can move while projecting relative to target molecules (e.g., sialic acid) expressed on the surface of the target cells, and it is expected that they can efficiently interact with the target molecules in a multivalent manner. Therefore, it is believed that boron drugs can be efficiently and tumor-selectively delivered.

[0155] Example

[0156] Hereinafter, the present invention will be specifically described with reference to Examples, but the present invention is not limited to the following Examples.

[0157] An example using FPBA-PRX (fluorophenylboronic acid-rotaxane), which is one embodiment of the boronic acid-containing modified polyrotaxane of the present invention, is described below.

[0158] (Example 1: Preparation of FPBA-PRX)

[0159] Figure 1 An example of the preparation route of FPBA-PRX is shown below. FPBA-PRX is prepared as follows. α-cyclodextrin (α-CyD) is dissolved in water, and polyethylene glycol (PEG-NH2) with amino groups at both ends is added, followed by stirring at 4°C overnight. After confirming the formation of a precipitate of polypseudorotaxane (PPRX), adamantane acetic acid and a condensing agent are added, and the mixture is stirred for 48 hours. The product is washed with purified water to remove unreacted α-CyD, PEG-NH2, and adamantane acetic acid, thereby obtaining a polyrotaxane (α-PRX) composed of α-CyD.

[0160] Next, to improve the solubility of α-PRX, α-PRX was dissolved in a 1N NaOH aqueous solution, reacted with propylene oxide, dialyzed against water, and freeze-dried to obtain hydroxypropylated PRX (HP-PRX). The resulting HP-PRX was dissolved in DMSO, reacted with 1,2-bis(2-aminoethoxy)ethane, dialyzed against water, and freeze-dried to obtain N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]amidated polyrotaxane (NH2-PRX).

[0161] 4-Carboxy-3-fluorophenylboronic acid (FPBA) (109 mg) was dissolved in DMSO (100 mL), and NHS (106.3 mg) and EDC (187.5 mg) were added. The mixture was stirred at room temperature for 5 hours to activate the carboxyl groups of FPBA. NH2-PRX (260 mg) was added to the activated FPBA, and triethylamine (136 μL) was added dropwise. The mixture was stirred at room temperature for 24 hours. Unreacted FPBA was then removed by dialysis (Spectra / Por (registered trademark) Membrane MWCO: 8 kDa, solvent: water), and the mixture was freeze-dried to obtain FPBA-PRX.

[0162] (Example 2: Structural Analysis of FPBA-PRX)

[0163] The FPBA-PRX obtained in Example 1 was 1 H-NMR spectrum analysis revealed the presence of anomeric protons of α-CyD at around 4.9 ppm and 5.1 ppm, a peak attributable to the ethoxy group of PEG at around 3.5 ppm, and a peak attributable to the CH group of FPBA at around 7.3-7.6 ppm, confirming the production of FPBA-PRX. The number of α-CyD per molecule of FPBA-PRX was calculated from the peak area ratio of α-CyD to PEG, resulting in approximately 54.4 α-CyD atoms. Since the PEG (20 kDa) used in the axial molecule theoretically allows for the permeation of a maximum of approximately 227 α-CyD atoms, the permeation rate of FPBA-PRX was calculated to be approximately 24%. Furthermore, a comparison of the peak areas of α-CyD and FPBA confirmed the incorporation of 0.79 FPBA atoms per molecule of CyD, resulting in a calculated number of approximately 43 FPBA atoms per molecule of FPBA-PRX. The total molecular weight of FPBA-PRX calculated based on the above values ​​was 107 kDa. The results are shown in the table below.

[0164] [Table 1]

[0165]

[0166] (Comparative Example 1: Preparation of FPBA-C)

[0167] As a control for FPBA having low mobility, FPBA-C (fluorophenylboronic acid-cellulose) was prepared. Figure 2 The preparation route of FPBA-C is shown in the figure. HPC (hydroxypropyl cellulose) is dissolved in DMSO and reacted with 1,2-bis(2-aminoethoxy)ethane. After dialysis in water, the mixture is freeze-dried to obtain N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]amidated HPC (NH2-C). FPBA (24.5 mg) is dissolved in DMSO (50 mL), and NHS (21.6 mg) and EDC (38.2 mg) are added. The mixture is stirred at room temperature for 5 hours to activate the carboxyl groups of FPBA. NH2-C (93.8 mg) is added to the activated FPBA, and triethylamine (28 μL) is added dropwise. The mixture is stirred at room temperature for 24 hours. Unreacted FPBA is then removed by dialysis, and the mixture is freeze-dried to obtain FPBA-C.

[0168] (Comparative Example 2: Analysis of FPBA-C)

[0169] The FPBA-C obtained in Comparative Example 1 was 1 H-NMR spectrum analysis. As a result, a peak of CH derived from cellulose was observed at around 4.3 ppm, and a peak of CH derived from FPBA was observed at around 7.3-7.6 ppm, confirming that FPBA-C was produced. Next, the peak areas of cellulose and FPBA were compared, and the results confirmed that approximately 35 FPBAs were introduced per molecule of cellulose. The number of FBPAs bonded to one molecule of cellulose was 35, which is considered to be roughly equivalent to the 43 FBPAs bonded to one molecule of rotaxane in Example 1, and therefore was judged to be suitable as a comparative example. Furthermore, it was confirmed that the total molecular weight of FPBA-C was approximately 116 kDa, and the chemical properties of FPBA-PRX and FPBA-C were roughly equivalent.

[0170] (Example 3: Evaluation of Physical Properties of FPBA-PRX: Particle Size and Zeta Potential)

[0171] In order to demonstrate the EPR effect, it is generally considered important that the particle size of the formulation be 200 nm or less and that the charge be neutral. The physicochemical properties of FPBA-PRX and FPBA-C prepared in Example 1 and Comparative Example 1 were evaluated. FPBA-PRX (0.53 mg / mL) or FPBA-C (0.58 mg / mL) was added to a 5% aqueous mannitol solution (1 mL, pH 7.4). After pipetting, the particle size and zeta potential were measured using a Malvern Zetasizer Nano-ZS. The measurement results are shown in the table below. Each value represents the mean ± SEM of three measurements.

[0172] [Table 2]

[0173]

[0174] The particle size of FPBA-PRX is approximately 15 nm, and the particle size of FPBA-C is approximately 12 nm. In addition, the ζ-potentials of both FPBA-PRX and FPBA-C were found to be near neutral. These results confirm that FPBA-PRX and FPBA-C have good particle properties as drug delivery system (DDS) materials. Therefore, it can be confirmed that FPBA-PRX is a particle that can be expected to be active-targeted using sialic acid (SA), as well as passively targeted using the EPR effect.

[0175] (Example 4: Evaluation of physical properties of FPBA-PRX: Confirmation of interaction with SA)

[0176] PBA is known to reversibly bond to 1,2- and 1,3-diols of sugars via boronic acid, and has been reported to interact with SA. In order to investigate whether FPBA-PRX interacts with SA, Alizarin Red S (ARS) was used for evaluation. ARS emits fluorescence by specifically binding to phenylboronic acid. FPBA-PRX solution (12 μM), ARS solution (500 μM) and SA solution (0, 20, 30, 40 mM) were prepared with PBS, and the FPBA-PRX solution (500 μL) was mixed with SA solution (500 μL) of various concentrations and allowed to stand at room temperature for 10 minutes. Subsequently, various concentrations of FPBA-PRX / SA mixed solution (500 μL) were added to the ARS solution (500 μL) and allowed to stand at room temperature for 10 minutes. Thereafter, the fluorescence from ARS was measured using a fluorescence plate reader. The results are shown in Figure 3 As shown in the figure, strong fluorescence was observed by adding FPBA-PRX to ARS. Furthermore, when various concentrations of SA were added, the fluorescence intensity from ARS decreased depending on the SA concentration. This suggests that FPBA-PRX interacts with SA.

[0177] Furthermore, the dissociation constants of FPBA-PRX and FPBA-C as a control with SA were evaluated by quartz crystal microbalance (QCM). The results confirmed that FPBA-PRX interacted more strongly with SA than FPBA-C.

[0178] (Example 5: Evaluation of FPBA-PRX Cytotoxicity)

[0179] HeLa cells were used to evaluate the cytotoxicity of FPBA-PRX as an indicator of safety evaluation. HeLa cells were cultured at a density of 1.5×10 4The cells were seeded in a 96-well cell culture plate in a cell / well manner and cultured for 24 hours with a medium containing 10% FBS. After washing the cells twice with serum-free medium, serum-free medium (100 μL) containing FPBA-PRX (0-25 μM) was added and treated for 4 hours. Thereafter, after washing with HBSS twice, HBSS (100 μL) and WST-8 solution (10 μL) were added, and after incubation at 37°C for 1 hour, the absorbance was measured with a microplate reader. In addition, the absorbance of the serum-free medium containing Tween20 (1%) and the system without added sample was set as 0% and 100% respectively to calculate the cell survival rate during sample treatment. As a result, since FPBA-PRX maintained a survival rate of approximately 100% at any concentration, it was confirmed that it itself did not show cytotoxicity to HeLa cells. Furthermore, the boron concentration in the maximum concentration of FPBA-PRX (25 μM) measured this time was 1.22 mM, which is approximately equivalent to the boron concentration in BPA commonly used clinically. This indicates that FPBA-PRX has biocompatibility suitable for clinical use.

[0180] (Example 6: Evaluation of intracellular uptake of FPBA-PRX)

[0181] SA is known to be present at the non-reducing ends of sugar chains on the cell surface, playing an important role in cell recognition. It is also highly expressed in cancer cells compared to normal cells. TRITC-FPBA-PRX and TRITC-FPBA-C, labeled with the fluorescent substance TRITC, and TRITC-HP-PRX, which is TRITC-labeled with unmodified FPBA (HP-PRX), were prepared and their intracellular uptake into various cancer cells and normal cells was studied using flow cytometry.

[0182] NH2-PRX (50 mg) was dissolved in DMSO (20 mL), TRITC solution (5 mg / mL, 200 μL) was added, and the mixture was stirred at room temperature for 24 hours to prepare TRITC-NH2-PRX. Next, FPBA (23 mg) was dissolved in DMSO (20 mL), NHS (20.5 mg) and EDC (36 mg) were added, and the mixture was stirred at room temperature for 5 hours to activate the carboxyl groups of FPBA. Activated FPBA was added to TRITC-NH2-PRX, and triethylamine (26 μL) was added dropwise. The mixture was stirred at room temperature for 24 hours, unreacted FPBA and TRITC were removed by dialysis, and the mixture was freeze-dried to prepare TRITC-FPBA-PRX.

[0183] TRITC-FPBA-C was prepared in the same manner using NH2-C (55 mg). TRITC-HP-PRX was prepared by reacting TRITC with NH2-PRX (50 mg) in the same manner, removing unreacted TRITC by dialysis, and freeze-drying.

[0184] The intracellular uptake was determined as follows. HeLa cells were plated at 3.75 × 10 4 Cells were seeded in a 24-well cell culture plate at a cell / well ratio and cultured for 24 hours in a medium containing 10% FBS. After washing twice with serum-free medium, the cells were treated for 4 hours with serum-free medium (500 μL) containing TRITC-FPBA-PRX, TRITC-FPBA-C, and TRITC-HP-PRX (0, 50, 100, and 200 nM, corresponding to the concentration of each polymer) or serum-free medium (500 μL) containing TRITC-FPBA-PRX and TRITC-FPBA-C (0, 2, 4, and 8 μM, corresponding to the concentration of FPBA in the polymer). The cells were then washed once with HBSS, detached from the plate using the trypsin-EDTA method, and the supernatant removed by centrifugation. HBSS containing 10% FBS (500 μL) was then added to prepare a cell suspension, and TRITC fluorescence was measured using flow cytometry. The TRITC modification amount in each sample was calibrated based on the TRITC-FPBA-PRX system.

[0185] Colon-26 cells were cultured at a volume of 1.0 × 10 5 Cells were seeded per well and cultured for 24 hours in a medium containing 10% FBS. After washing twice with serum-free medium, cells were added with serum-free medium (500 μL) containing TRITC-FPBA-PRX, TRITC-FPBA-C, and TRITC-HP-PRX (0, 100, 200, and 500 nM, corresponding to the concentration of each polymer), or serum-free medium (500 μL) containing TRITC-FPBA-PRX and TRITC-FPBA-C (0, 5, 10, and 20 μM, corresponding to the concentration of FPBA in the polymer) for 4 hours. Cells were then washed once with HBSS, peeled from the plate, and fluorescence was measured in the same manner.

[0186] The results of Hela cells are shown in Figure 4 The results of Colon-26 cells are shown in Figure 5 . Figure 4 A and Figure 5A represents the results of evaluating the uptake ability of TRITC-FPBA-PRX, TRITC-HP-PRX, and TRITC-FPBA-C into various cancer cells while keeping the polymer concentrations contained therein constant. Figure 4 B and Figure 5 B is the result of evaluating the uptake ability of various cancer cells by keeping the FPBA concentration constant. Figure 4 As shown in Figure 2, it was confirmed that TRITC-HP-PRX without FPBA modification and TRITC-FPBA-C, whose ligand is low in mobility, were hardly incorporated into HeLa cells. In contrast, TRITC-FPBA-PRX was incorporated into HeLa cells efficiently and in a concentration-dependent manner. Figure 4 As shown in Figure B, the same trend was also confirmed when the FPBA concentration was constant. Figure 5 As shown in the results, it was confirmed that TRITC-FPBA-PRX was efficiently incorporated into Colon-26 cells compared to TRITC-HP-PRX and TRITC-FPBA-C. These results suggest that the dynamic properties of PRX-modified FPBA are important for efficient intracellular uptake.

[0187] It is believed that FPBA-PRX is internalized via SA, which is highly expressed on the surface of cancer cells, and is not internalized by normal cells. Next, as a safety assessment of FPBA-PRX, the internalization of FPBA-PRX into normal human kidney cells (HK2 cells), which are generally considered to have low SA expression, was evaluated using flow cytometry.

[0188] HK2 cells were cultured to a volume of 5.0 × 10 4 Cells were seeded at 400 μL per well and cultured for 24 hours in a medium containing 10% FBS. After washing twice with serum-free medium, cells were added with 500 μL of serum-free medium containing TRITC-FPBA-PRX and TRITC-HP-PRX (0 and 200 nM) for 4 hours. Cells were then washed once with HBSS, removed from the plate, centrifuged, and the supernatant removed. After preparing a cell suspension, 500 μL of HBSS containing 10% FBS was added, and TRITC fluorescence was measured using a flow cytometer.

[0189] The results are shown in Figure 6 The figure confirms that TRITC-FPBA-PRX is barely taken up by HK2 cells, and its uptake is roughly comparable to that of HP-PRX. These results confirm that TRITC-FPBA-PRX, through PRXization, generates dynamic multivalent interactions with SA, enabling more active uptake into various cancer cells that highly express SA, compared to low-mobility polymers.

[0190] (Example 7: In vivo dynamic evaluation of FPBA-PRX)

[0191] FPBA-PRX was administered intravenously to healthy mice, and the blood retention was confirmed as follows. A 5% mannitol solution (100 μL) containing TRITC-FPBA-PRX fluorescently labeled with TRITC was administered into the tail vein of mice (BALB / c). The dosage was 5.8 mg / kg. After 5, 10, 30, 60, 180 and 360 minutes, blood (200 μL) was collected from the inferior vena cava in the abdomen under isoflurane anesthesia. After centrifugation, the blood collected from the mice was separated into plasma (100 μL), and the fluorescence of TRITC was measured using a fluorescence plate reader. In addition, TRITC-FPBA-PRX and TRITC-FPBA-C were dissolved in plasma and a calibration curve was prepared by serial dilution. The blood drug concentration was calculated from the fluorescence intensity to evaluate the blood retention of FPBA-PRX. The results of blood drug concentration after intravenous administration of TRITC-FPBA-PRX are shown in Figure 7 It was confirmed that approximately 12% of the administered dose of TRITC-FPBA-PRX remained in the blood 60 minutes after administration, and approximately 9% of the administered dose remained in the blood 360 minutes after administration.

[0192] (Example 8: Evaluation of Tumor Aggregation of FPBA-PRX)

[0193] According to Example 7, it was confirmed that when FPBA-PRX was administered intravenously to healthy mice, about 88% of the administered dose disappeared from the blood 60 minutes after administration. Therefore, FPBA-PRX was administered intravenously to tumor-bearing mice, and the tumor aggregation was evaluated as follows. In order to clarify the tumor aggregation after intravenous administration of FPBA-PRX, a single administration of TRITC-FPBA-PRX or TRITC-FPBA-C was performed into the tail vein of tumor-bearing mice transplanted with Colon-26 cells. The tumor was recovered and the fluorescence intensity of TRITC was measured for evaluation. Colon-26 cell suspension (5x10 5 cells / 100 μL) were used to prepare mice subcutaneously transplanted with Colon-26 cells. About one week later, mice whose tumors had a long diameter of 8 mm were used for experiments.

[0194] A 5% mannitol solution (100 μL) containing TRITC-FPBA-PRX or TRITC-FPBA-C was administered into the tail vein of the mice. The dosage was 5.8 mg / kg. After 30, 180, and 360 minutes, perfusion was performed under isoflurane anesthesia, and the tumor and various organs (heart, lungs, spleen, liver, and kidneys) were removed. The removed tumors and organs were dissolved in cell lysate and homogenized. Thereafter, centrifugation was performed, and the supernatant was separated. After further centrifugation, the supernatant was separated, and the fluorescence of TRITC was measured using a fluorescence plate reader. In addition, TRITC-FPBA-PRX or TRITC-FPBA-C was dissolved in the lysates of the tumor and various organs, and a calibration curve was prepared by serial dilution. The concentration in the tumor and various organs was calculated from the fluorescence intensity.

[0195] The results of tumor accumulation rates after a single administration of TRITC-FPBA-PRX or TRITC-FPBA-C into the tail vein are shown in Figure 8 Approximately 10% of the administered dose of TRITC-FPBA-PRX accumulated in tumors 180 minutes after administration, and approximately 15% of the administered dose accumulated in tumors 360 minutes after administration. Furthermore, it was confirmed that TRITC-FPBA-PRX exhibited a higher tumor accumulation rate than TRITC-FPBA-C.

[0196] Although not bound by this theory, the following considerations can be made. It is expected that FPBA-C will show the EPR effect as a high molecular weight, and further, through the multivalent interaction with SA, approximately 5% aggregation was confirmed, but FPBA-PRX was confirmed to be more efficiently aggregated in tumors than FPBA-C, showing very significant aggregation. As the main factor for FPBA-PRX to show high tumor aggregation, as shown in Table 2, it is believed that FPBA-PRX has physical properties suitable for the EPR effect, and that it acts based on the dynamic multivalent interaction of FPBA. In addition, it was also confirmed that FPBA-PRX interacts with SA with a higher association constant than FPBA-C. In summary, it is believed that after intravenous administration, FPBA-PRX utilizes the EPR effect to aggregate in tumor tissues, and prompts FPBA on demand according to the distribution of SA on the cell surface. As a result, it is efficiently taken up into the tumor tissue via SA, thereby avoiding excretion by the reverse transporter, thereby showing excellent tumor aggregation.

[0197] (Example 9: Evaluation of Tissue Distribution of FPBA-PRX)

[0198] The tissue metastasis of TRITC-FPBA-PRX to various tissues removed in Example 8 was evaluated using the fluorescence intensity of TRITC as an indicator. The results are shown in Figure 9. As shown in the figure, it was confirmed that TRITC-FPBA-PRX accumulated most in the tumor 3 hours after intravenous administration, and accumulated more in the tumor than in other organs until at least 6 hours after administration. On the other hand, it was confirmed that TRITC-FPBA-C accumulated in some tumors, but mainly accumulated in the liver, kidneys and spleen. It is generally known that high molecular polymers are phagocytosed by the reticuloendothelial system (RES) after intravenous administration. In fact, it is believed that since FPBA-C has lower tumor selectivity than FPBA-PRX, it is phagocytosed by the RES and accumulates in the liver or spleen in a time-dependent manner. This confirms that FPBA-PRX is rapidly transferred to the tumor after intravenous administration, avoids phagocytosis by the RES, and is taken up into cancer cells via SA.

[0199] (Example 10: Evaluation of T / B ratio)

[0200] In boron neutron capture therapy, it is important to evaluate the tumor / blood ratio (T / B ratio) and tumor / normal tissue ratio (T / N ratio) of the boron agent after intravenous administration during neutron beam irradiation from the perspective of safety. As in Example 8, a single intravenous administration of TRITC-FPBA-PRX or TRITC-FPBA-C (5.8 mg / kg) was performed on tumor-bearing mice, and the T / B ratio was measured 3, 6, and 24 hours later. The results are shown in Figure 10 The T / B ratio of TRITC-FPBA-PRX was approximately 3 or higher 24 hours after administration, and was higher than that of TRITC-FPBA-C at all times. According to the BNCT irradiation system development guidelines, BNCT requires a T / B ratio and a T / N ratio of 3 or higher for safety reasons. The FPBA-PRX of the present invention was confirmed to meet this requirement and exhibit excellent cancer selectivity.

[0201] (Example 11: Evaluation of Safety of FPBA-PRX)

[0202] In order to evaluate the safety of FPBA-PRX, FPBA-PRX was administered to mice and blood biochemical test values ​​were measured. A single dose of 5% mannitol solution (100 μL) containing TRITC-FPBA-PRX (5.8 mg / kg) was administered to the tail vein of BALB / c male mice (4 weeks old, 20 g). 24 hours after administration, blood was collected from the inferior vena cava in the abdomen under isoflurane anesthesia. The blood collected from the mice was centrifuged and the plasma was separated. The determination of various blood biochemical test values ​​was quantitatively performed using a fully automatic hematology analyzer. Saline was administered as a control. The measurement results are shown in the table below. Each numerical value represents the mean ± SEM of each measured value of 4 mice. CRE: creatinine, BUN: blood urea nitrogen, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase.

[0203] [Table 3]

[0204]

[0205] As shown in the table, FPBA-PRX showed values ​​comparable to those of the saline group in all test items, confirming the possibility that FPBA-PRX has excellent in vivo safety.

[0206] (Example 12: Evaluation of Boronic Acid-Containing Modified Polyrotaxanes to Which Folic Acid-Modified β-CyD is Bonded)

[0207] Folate receptor molecules are known to be overexpressed on the surface of cancer cells, and reports suggest that folic acid could potentially serve as a ligand for cancer cell-targeting drug systems. Furthermore, folic acid-modified β-cyclodextrin, in which folic acid is bound as a ligand, has been reported for the purpose of DDS targeting cancer cells.

[0208] Folic acid-modified β-cyclodextrin (FA7-β-CyD) was bound to TRITC-FPBA-PRX prepared in the same manner as in Example 6 to prepare a modified polyrotaxane containing boronic acid bound to folate-modified β-CyD, and its uptake into cells was evaluated. Figure 11 As shown, it is believed that the folic acid-modified β-CyD is bonded to adamantane as a capping group.

[0209] Colon-26 cells were cultured at a volume of 1.0 × 10 5The cells were seeded in a cell / well manner and cultured for 24 hours with a medium containing 10% FBS. After washing the cells twice with serum-free medium, a medium containing folic acid (0.5-2mM) was added and cultured for 1 hour. Next, a medium containing TRITC-FPBA-PRX and FA7-β-CyD (a medium containing TRITC-FPBA-PRX / FA7-β-CyD) was added and cultured for 4 hours. Thereafter, the cells were washed once with HBSS, peeled from the plate, and the supernatant was removed by centrifugation. HBSS containing 10% FBS was added to prepare a cell suspension, and the fluorescence of TRITC was measured by flow cytometry. In order to confirm the effect of FA7-β-CyD, a medium containing TRITC-FPBA-PRX / FA7-β-CyD was used to further add folic acid. The results are shown in Figure 12 It was confirmed that the addition of FA7-β-CyD increased the uptake of TRITC-FPBA-PRX into cells, and that this effect was suppressed in a concentration-dependent manner by the addition of folic acid to the culture medium. Thus, it was confirmed that the cell aggregation of FPBA-PRX was enhanced by the binding of folic acid-modified cyclodextrin to TRITC-FPBA-PRX.

[0210] (Example 13: Evaluation of PEG-dopamine-modified boronic acid-containing modified polyrotaxane)

[0211] It has been reported that by bonding PEG to a molecule, blood retention is improved, and the effect of avoiding recognition of normal tissues is expected to improve targeting to cancer cells.

[0212] PEG dopamine was bonded to FPBA-PRX prepared in the same manner as in Example 6 to prepare a modified polyrotaxane containing boronic acid to which PEG dopamine was bonded, and its uptake into cells was evaluated. Figure 11 As shown, the diol site of PEG dopamine is thought to be reversibly bonded to boronic acid. This bond is thought to be maintained at a pH near neutral in blood but dissociated at an acidic pH near cancer cells.

[0213] HeLa cells were cultured to a size of 5.0 × 10 4 The cells were seeded in a cell / well format and cultured for 24 hours with a medium containing 10% FBS. After washing the cells with serum-free medium, a mixed solution of TRITC-FPBA-PRX and PEG dopamine (the concentration ratio of TRITC-FPBA-PRX:PEG dopamine = 1:1, 1:2 and 1:4) was added and cultured for 4 hours. Thereafter, the cells were washed with HBSS, peeled off from the plate using the trypsin-EDTA method, and the supernatant was removed by centrifugation. HBSS containing 10% FBS (500 μL) was added to prepare a cell suspension, and the fluorescence of TRITC was measured using a flow cytometer. The results are shown in Figure 13 When the relative ratio of PEG dopamine increases, the ratio of boronic acid bonded to PEG dopamine increases, and as a result, it is speculated that the uptake of SA into cells decreases.

[0214] Next, the uptake into cells was tested at pH 7.4 and pH 6.5. The results showed that the uptake into cells was significantly increased at pH 6.5 compared to pH 7.4. Figure 14 From this, it is speculated that by shifting the pH to the acidic side, the bond between boric acid and PFG dopamine is dissociated, and the uptake into cells is increased.

[0215] (Example 14: Evaluation of cytotoxicity to cancer cells)

[0216] The cytotoxicity of HeLa cells to 5.0×10 4 The cells were seeded in a cell / well format and cultured for 24 hours with a medium containing 10% FBS. The medium was removed, washed with PBS, and then DMEM medium (500 μL) containing trypsin 2.5 mg / mL and FPBA-PRX (12 mg / mL) was added and cultured for 3 hours. Thereafter, the cells were washed twice with PBS, and then HBSS (100 μL) and WST-8 solution (10 μL) were added. After incubation at 37°C for 30 minutes, the absorbance was measured with a microplate reader. The results are shown in Figure 15 It was confirmed that FPBA-PRX exhibited cytotoxicity against cancer cells.

[0217] (Example 15: Evaluation of antitumor activity)

[0218] Colon26 cells were transplanted into the right thigh of BALB / c mice (9-week-old, male, n=4-5 per group) and maintained until the tumor reached a diameter of approximately 7-9 mm. The mice's body weight and tumor size were measured the day before irradiation, and the mice were grouped according to tumor volume. Group A: Control; Group B: FPBA-PRX-administered group; Group C: Neutron-irradiated group; Group D: FPBA-PRX-administered + Neutron-irradiated group. Six hours before irradiation, the FPBA-PRX-administered groups (Groups B and D) received 500 mg / kg (administered at a concentration of 100 mg / mL) of FPBA-PRX via the tail vein. This is equivalent to 10 mg / kg when converted to 10B concentration. The administration lasted for six hours. In the neutron-irradiated groups (Groups C and D), anesthetics were administered intraperitoneally. After securing the mice in the irradiation container, neutron irradiation (4800 mC, 40 minutes) was performed. Following irradiation, an antagonist was administered intraperitoneally to confirm recovery. The results are shown in Figure 16The graph shows the average tumor size of the non-irradiated group and the average tumor size of the irradiated group. Tumor suppression was observed in the FPBA-PRX administration + neutron irradiation group compared to the neutron irradiation group.

[0219] The above detailed description simply illustrates the purpose and object of the present invention and does not limit the scope of protection of the attached patent claims. According to the teachings recorded in this specification, various changes and substitutions of the described embodiments without departing from the scope of protection of the attached patent claims will be obvious to those skilled in the art.

[0220] This application is based on Japanese Patent Application No. 2022-46218 (filing date: March 23, 2022) filed in Japan, the entire contents of which are incorporated herein by reference.

[0221] Industrial applicability

[0222] The present invention provides a novel compound containing a boronic acid modified polyrotaxane. The boronic acid modified polyrotaxane of the present invention has excellent blood retention and tumor selectivity and can be used as a component of a novel boron drug, and is therefore useful.

Claims

1. A modified polyrotaxane containing boric acid, comprising: a plurality of cyclodextrin molecules, a linear molecule that penetrates through the openings of the plurality of cyclodextrin molecules in a string-like manner, and end-capping groups that are arranged at both ends of the linear molecule and prevent the cyclodextrin molecules from separating from the linear molecules, wherein at least a portion of the cyclodextrin molecules is bonded to a monovalent group derived from boric acid or a derivative thereof via a linking group.

2. The modified polyrotaxane containing boronic acid according to claim 1, in, The monovalent group derived from boronic acid or a derivative thereof is a monovalent group derived from a phenylboronic acid derivative or a pyridineboronic acid derivative.

3. The modified polyrotaxane containing boronic acid according to claim 2, in, The monovalent group derived from boric acid or a derivative thereof is a group represented by the following formula (B1) or the following formula (B2), In the formula, Ra represents a hydrogen atom or a halogen atom, and Rb represents -(CH 2 )n-CO-*、-(CH 2 )n-NH-*、-(CH 2 )n-CH(NHR)CO-*or-(CH 2 )n-CH(C(O)OR)NH-*, wherein * represents a bond to a connecting group, n represents 0, 1 or 2, and R represents a hydrogen atom or a C1-C5 hydrocarbon group which may have a substituent, In the formula, Rc represents -(CH 2 )n-CO-*、-(CH 2 )n-NH-*、-(CH 2 )n-CH(NHR)CO-*or-(CH 2 )n-CH(C(O)OR)NH-*, wherein * represents a bond to a connecting group, n represents 0, 1 or 2, and R represents a hydrogen atom or a C1-C5 hydrocarbon group which may have a substituent.

4. The modified polyrotaxane containing boronic acid according to claim 3, in, The monovalent group derived from boric acid or a derivative thereof is a group represented by the following formula (B3) or the following formula (B4), In the formula, Ra represents a hydrogen atom or a halogen atom, and Rb represents -(CH 2 )n-CO-*、-(CH 2 )n-NH-*、-(CH 2 )n-CH(NH 2 )CO-* or -(CH 2 )n-CH(C(O)OH)NH-*, wherein * represents a bond to a linking group, and n represents 0 or 1, In the formula, Rc represents -(CH 2 )n-CO-*、-(CH 2 )n-NH-*、-(CH 2 )n-CH(NH 2 )CO-* or -(CH 2 )n-CH(C(O)OH)NH-*, wherein * represents a bond to a connecting group, and n represents 0 or 1.

5. The modified polyrotaxane containing boronic acid according to claim 4, in, The monovalent group derived from boronic acid or a derivative thereof is a monovalent group derived from a boronic acid derivative selected from 4-carboxy-3-fluorophenylboronic acid, 6-carboxypyridine-3-boronic acid (5-boropyridinecarboxylic acid), 4-carboxyphenylboronic acid, p-boronic phenylalanine, 4-amino-3-fluorophenylboronic acid and 5-aminopyridine-3-boronic acid.

6. The modified polyrotaxane containing boronic acid according to any one of claims 1 to 5, in, The linear molecule is polyethylene glycol, polypropylene glycol, or a copolymer of polyethylene glycol and polypropylene glycol.

7. The modified polyrotaxane containing boronic acid according to any one of claims 1 to 6, in, The end-capping group is adamantyl.

8. The modified polyrotaxane containing boronic acid according to any one of claims 1 to 7, in, The plurality of cyclodextrin molecules are a plurality of α-cyclodextrin molecules.

9. The modified polyrotaxane containing boronic acid according to any one of claims 1 to 8, in, The linking group is represented by formula (L1), In the formula, * 1 is the bonding site with the cyclodextrin molecule,* 2 is a bonding site with a group containing boronic acid, R 1 each independently represents a hydrogen atom, a carboxyl group which may be substituted by an alkyl group having 1 to 6 carbon atoms, a hydroxyl group which may be substituted by an alkyl group having 1 to 6 carbon atoms, a mercapto group which may be substituted by an alkyl group having 1 to 6 carbon atoms, an aryl group having 6 to 14 carbon atoms, or an alkyl group having 1 to 6 carbon atoms, Q each independently represents -O-, -S-, -NH-, -SO 2 -, -CO-, -NHCO-, -CONH-, -OCO-, -COO-, -SCO-, -COS-, -NHCONH-, -NHCSNH-, -OCONH- or -NHCOO-, a each independently represents an integer of 1 to 6, b represents an integer from 1 to 6, c represents an integer from 1 to 6, X 1 Each independently represents -O-, -S-, -NH-, -SO 2 -, -CO-, -NHCO-, -CONH-, -OCO-, -COO-, -SCO-, -COS-, -NHCONH-, -NHCSNH-, -OCONH- or -NHCOO-.

10. The modified polyrotaxane containing boronic acid according to claim 9, in, The linking group is represented by formula (L2), In the formula, * 1 is the bonding site with the cyclodextrin molecule,* 2 is a bonding site with a group containing boronic acid, d represents an integer from 1 to 6, e represents an integer from 1 to 3, X 2 Each independently represents -O-, -S-, -NH-, -SO 2 -, -CO-, -NHCO-, -CONH-, -OCO-, -COO-, -SCO-, -COS-, -NHCONH-, -NHCSNH-, -OCONH- or -NHCOO-.

11. The modified polyrotaxane containing boronic acid according to any one of claims 1 to 10, in, In the polyrotaxane whose end-capping group is an adamantyl group, the folic acid-modified β-cyclodextrin is further bonded to the adamantyl group.

12. The modified polyrotaxane containing boronic acid according to claim 11, in, The plurality of cyclodextrin molecules are α-cyclodextrin molecules, and the linear molecule is polyethylene glycol.

13. The modified polyrotaxane containing boronic acid according to any one of claims 1 to 12, in, Dopamine modified with polyethylene glycol is further bonded to boronic acid.

14. A pharmaceutical composition for boron neutron capture therapy of tumor diseases, comprising the modified polyrotaxane containing boronic acid according to any one of claims 1 to 13, in, The boron of the boric acid is 10B.

15. A method for treating tumor diseases using boron neutron capture therapy, It is characterized in that A method for administering a required amount of the modified polyrotaxane containing boronic acid according to any one of claims 1 to 13 to a mammal, wherein the boron of the boronic acid is 10B.